2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinoma
2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive marginsDisparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic
Javier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.Peer-Reviewed Original ResearchConceptsTelemedicine utilizationMultivariable logistic regression analysisLogistic regression multivariable analysisRegression multivariable analysisSingle academic institutionLogistic regression analysisUse of telemedicineCOVID-19 pandemicNon-Hispanic whitesUrology patientsPatient characteristicsPrimary outcomeMedicaid insuranceMultivariable analysisRetrospective studyTelemedicine appointmentsUrologic conditionsProvider ageProvider trainingClinic locationProvider sexPatientsBackward model selectionZip codesVisits
2021
Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients
Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.Peer-Reviewed Original ResearchConceptsNon-Hispanic white patientsCancer-specific survivalRenal cell carcinomaMedically Underserved AreasCause mortalityWhite patientsHealth care system accessSpecific survivalNon-Hispanic whitesLocalized Renal Cell CarcinomaTertiary referral centerCause mortality riskKaplan-Meier analysisLog-rank testCancer surgical outcomesOverall survivalReferral centerSecondary outcomesPrimary outcomeHispanic patientsMeier analysisCox regressionSurgical outcomesCell carcinomaRisk factors
2020
Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.Peer-Reviewed Original ResearchConceptsKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaRecurrence-free survivalRadical nephrectomyPartial nephrectomyOverall survivalMultivariable analysisCell carcinomaFunctional outcomeDe novo eGFRGlomular filtration rateClinical T stageMulticenter retrospective analysisRisk of recurrenceMulti-institutional analysisPT3a upstagingOncologic outcomesSecondary outcomesPrimary outcomeIndependent predictorsSurvival outcomesT stagePositive marginsPredictive factorsMulticenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma.
Bradshaw A, Ghali F, Miller N, Keiner C, Dutt R, Meagher M, Yim K, Patel D, Uzzo R, Lane B, Capitanio U, Derweesh I. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 758-758. DOI: 10.1200/jco.2020.38.6_suppl.758.Peer-Reviewed Original ResearchRecurrence-free survivalCancer-specific survivalKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaOverall survivalMultivariable analysisSecondary outcomesPrimary outcomeCell carcinomaT3a renal cell carcinomaPathologic tumor sizePoor oncologic outcomesRegression multivariable analysisClear cell histologyLog-rank testPre-operative imagingPositive margin rateHigh recurrence rateAdvanced diseaseCell histologyOncologic outcomesVenous involvementMulticenter analysisOS rates
2019
Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria
Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRisk of recurrenceRenal cell carcinomaKaplan-Meier analysisHigher clinical stageClinical stageOverall survivalMultivariable analysisPT3a upstagingRisk factorsTumor-NodeT3a renal cell carcinomaRenal cell carcinoma patientsRisk of upstagingCell carcinoma patientsMulticenter retrospective analysisPerinephric fat invasionInitial clinical stageRenal vein invasionType of surgeryPT3a diseaseCarcinoma patientsPrimary outcomeFat invasionRenal vein